|
| Friday, February 6, 2026 |
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets |
| On February 6, 2026, according to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672. HK). more info >> |
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share |
| on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by acquiring 64,128,000shares at a price of HKD12.18per share more info >> |
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元 |
| 2026年2月6日報道，根據香港聯交所2月6日披露的文件，新加坡政府投資公司（GIC Private Limited）於2月5日首次入股歌禮製藥（01672）。 more info >> |
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元 |
| 2026年2月6日报道，根据香港联交所2月6日披露的文件，新加坡政府投资公司（GIC Private Limited）于2月5日首次入股歌礼制药（01672）。 more info >> |
|
| Thursday, February 5, 2026 |
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share |
| According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). more info >> |
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司入股6412.8萬股 涉資約1億美元 |
| 根據香港聯交所披露的文件，新加坡政府投資公司（GIC Private Limited）入股歌禮製藥，以每股均價12.18 港元，買入 64,128,000 股普通股股份，合計涉資約7.81億港元，折合約1億美元。 more info >> |
|
|
歌礼制药-B（01672）获新加坡政府投资公司入股6412.8万股 涉资约1亿美元 |
| 根据香港联交所披露的文件，新加坡政府投资公司（GIC Private Limited）入股歌礼制药，以每股均价12.18 港元，买入 64,128,000 股普通股股份，合计涉资约7.81亿港元，折合约1亿美元。 more info >> |
|
| Wednesday, August 1, 2018 |
|
|
Ascletis Successfully Listed on the Main Board of HKEX |
| Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital market has been opened up further, welcoming listing applications from several biotechnology companies. more info >> |
|
|
中國首個原研全口服丙肝治愈方案上市申請獲受理 |
| 歌禮今日宣布，公司向國家藥品監督管理局遞交的中國首個原研全口服丙肝治愈方案上市申請已獲受理。 more info >> |
|
|
中国首个原研全口服丙肝治愈方案上市申请获受理 |
| 歌礼今日宣布，公司向国家药品监督管理局递交的中国首个原研全口服丙肝治愈方案上市申请已获受理。 more info >> |
|
|
|
|
